Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

Unitat de Recerca Biomèdica i Oncologia Translacional (GRC)

IP: Jaume Reventós Puigjaner
Collaborators: José Placer Santos, Joan Morote Robles, Maria Asuncion Perez Benavente, Eva Colas Ortega, Silvia Cabrera Diaz, Antonio Gil Moreno, Jacques Planas Morin
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50000
Reference: 2014 SGR 1330
Duration: 01/01/2014 - 31/12/2016

Desarrollo de algoritmos predictivos de riesgo de recidiva y respuesta a terapia en cáncer de endometrio

IP: Eva Colas Ortega
Collaborators: -
Funding agency: Fundació Santiago Dexeus Font
Funding: 6000
Reference: FSDF-2013-03
Duration: 31/01/2014 - 31/01/2016

ProstatePredict. Desarrollo de una prueba de pronóstico para predecir la probabilidad de enfermedad agresiva después de la cirugía

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 150405
Reference: IPT-2012-1311-300000
Duration: 17/12/2012 - 30/04/2016

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Inés de Torres Ramirez, Maria Asuncion Perez Benavente, Eva Colas Ortega, Silvia Cabrera Diaz, Antonio Gil Moreno, Carles Xavier Raventós Busquets, Jacques Planas Morin, Anna Santamaria Margalef
Funding agency: Instituto de Salud Carlos III
Funding: 229500
Reference: RD12/0036/0035
Duration: 01/01/2013 - 30/06/2017

Related news

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

Related professionals

Maria Pallares Masmitja

Maria Pallares Masmitja

Postdoctoral researcher
Gene and Cell Therapy
Read more
Piero Arturo Alberti Delgado

Piero Arturo Alberti Delgado

Predoctoral researcher
General Surgery
Read more
Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Palomar Muñoz, Azahara Maria

Palomar Muñoz, Azahara Maria

Molecular Imaging and Therapy
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.